Skip to main content

Pre-Analytic Phase: Test Selection; Specimen Acquisition and Handling

  • 166 Accesses


The Pre-analytical phase begins the at the moment the blood supply to the tissue is interrupted in taking the biopsy or resecting the lesion. It ends with the cutting of tissue sections for subsequent examination by morphologic methods, or extraction methods for molecular or genetic methods.

This is a preview of subscription content, access via your institution.

Buying options

USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-84087-7_5
  • Chapter length: 7 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-84087-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Fig. 5.1


  • Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22:4619–25.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  • Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.

    CAS  PubMed  Google Scholar 

  • Barisoni L, Lafata KJ, Hewitt SM, et al. Digital pathology and computational image analysis in nephropathology. Nat Rev Nephrol. 2020;16:669–85.

    CrossRef  PubMed  Google Scholar 

  • Bhargava R, Clark BZ, Carter GJ, Brufsky AM, Dabbs DJ. The healthcare value of the Magee decision algorithm™: use of Magee equations™ and mitosis score to safely forgo molecular testing in breast cancer. Mod Pathol. 2020;33(8):1563–70.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  • Cheung CC, D’Arrigo C, Dietel M, Francis GD, Fulton R, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine—part 4: tissue tools for quality assurance in immunohistochemistry. From the international society for immunohistochemistry and molecular morphology (ISIMM) and international quality network for pathology (IQN path). Appl Immunohistochem Mol Morph. 2017;25:227–30.

    CAS  CrossRef  Google Scholar 

  • Dodson A, Parry S, Lissenberg-Witte B, Haragan A, Allen D, O’Grady A, McClean E, Hughes J, Miller K, Thunissen E. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. J Pathol. 2019.

  • Hewitt SM, Robinowitz M, Bogen SA, Gown AM, Kalra KL, Otis CN, Spaulding B, Taylor CR. Quality assurance for design control and implementation of immunohistochemistry assays: approved guidelines, vol. 31. 2nd ed. Wayne. PA: Clinical Lab Standards Institute; 2011. p. 4.

    Google Scholar 

  • Kinney MC, Higgins RA, Am M. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med. 2011;135:19–43.

    CrossRef  PubMed  Google Scholar 

  • Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper DA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade a systematic review and meta-analysis. Jama Oncol. 2019.

  • NordiQC. Assessment run C5 2019. PD-L1 (lung). 2019.

  • Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J, Taylor CR, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non small cell lung cancer. Appl Immunohistochem Mol Morph. 2015;23:541–9.

    CAS  CrossRef  Google Scholar 

  • Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzuna HD, Taylor CR, Cogswell J, Novotny J, Oroudjev E, Winther H. Development of a diagnostic programmed cell death 1-ligand 1 immunohistochemistry assay for nivolumab therapy in melanoma. Appl Immunohistochem Mol Morph. 2018;26:6–12.

    CAS  CrossRef  Google Scholar 

  • Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 2019;20:1115.

    CAS  CrossRef  PubMed Central  Google Scholar 

  • Sheppard E, Madej RM, Alfaro MP, et al. Collection, transport, preparation, and storage of specimens for molecular methods. 2nd ed. Wayne, PA: Clinical Lab Standards Institute; 2020. MM13

    Google Scholar 

  • Skidmore L, Sakamuri S, Knudsen KA, Hewet AG, Milutinovic S, Barkho W, Biroc SL, Kirtley J, Marsden R, Storey K, Lopez I, Yu W, Fang S-Y, Yao S, Gu Y, Tian F. ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1–resistant breast and gastric cancers. Mol Cancer Ther. 2020;19:1833–43.

    CAS  CrossRef  PubMed  Google Scholar 

  • Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer. 1996;77:2419–22.

    CAS  CrossRef  PubMed  Google Scholar 

  • Taylor CR. Whole slide imaging- issues for use in diagnostic pathology: ‘routine;’ stains, immunohistochemistry and predictive markers. Biotech Histochem. 2014;89:419–23.

    CAS  CrossRef  PubMed  Google Scholar 

  • Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu E, Swanson P, Taylor CR, Vyberg M. Standardization of positive controls and introduction of immunohistochemistry critical assay performance controls (iCAPCs) in diagnostic immunohistochemistry: recommendations from the international ad hoc committee. Appl Immunohistochem Mol Morph. 2015;23:1–18.

    CAS  CrossRef  Google Scholar 

  • Verma S, Kumar M, Kumari M, Mehrotra R, RAS K, Goel M, Kumar A, Kant S. An immunohistochemical study of anaplastic lymphoma kinase and epidermal growth factor receptor mutation in non-small cell lung carcinoma. J Clin Diagn Res. 2017;11:EC22–5.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  • Yaziji H, Taylor CR. PD-L1 assessment for targeted therapy testing in cancer: urgent need for realistic economic and practice expectations. Appl Immunohistochem Mol Morph. 2017;25:1–3.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Jasani, B., Huss, R., Taylor, C.R. (2021). Pre-Analytic Phase: Test Selection; Specimen Acquisition and Handling. In: Precision Cancer Medicine. Springer, Cham.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84086-0

  • Online ISBN: 978-3-030-84087-7

  • eBook Packages: MedicineMedicine (R0)